Successful use of infliximab in macrophage activation syndrome with severe CNS involvement

Scandinavian Journal of Rheumatology

Volumn 40, Issue 2, 2011, Pages 156-157

  Sellmer, A ^a   Stausbol Gron B ^a   Krag Olsen, B ^b   Herlin, T ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b Department of Paediatrics Randers   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; AMPICILLIN; ASPARTATE AMINOTRANSFERASE; C REACTIVE PROTEIN; CYCLOSPORIN A; GENTAMICIN; GLUTAMIC ACID; GLUTAMINE; HEMOGLOBIN; INFLIXIMAB; METHYLPHENIDATE; METHYLPREDNISOLONE;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTHRALGIA; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; ATTENTION DEFICIT DISORDER; BONE MARROW EXAMINATION; BRAIN RADIOGRAPHY; BRAIN STEM; CASE REPORT; CENTRAL NERVOUS SYSTEM DISEASE; CHEYNE STOKES BREATHING; CHILD; DRUG MEGADOSE; ECHOGRAPHY; ELECTROENCEPHALOGRAPHY; FRONTAL CORTEX; GLASGOW COMA SCALE; GRANULOPOIESIS; HUMAN; HYPERREFLEXIA; LABORATORY TEST; LETTER; LEUKOCYTE COUNT; MACROPHAGE ACTIVATION SYNDROME; MALE; MYALGIA; NUCLEAR MAGNETIC RESONANCE IMAGING; PHYSICAL EXAMINATION; PRIORITY JOURNAL; RASH; SCHOOL CHILD; THROMBOCYTE COUNT;

ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; BRAIN; CENTRAL NERVOUS SYSTEM DISEASES; CHILD; CYTOKINES; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; MACROPHAGE ACTIVATION SYNDROME; MAGNETIC RESONANCE IMAGING; MALE; TREATMENT OUTCOME;

EID: 79952421684     PISSN: 03009742     EISSN: 15027732     Source Type: Journal    
DOI: 10.3109/03009742.2010.508468     Document Type: Letter

References (10)

1. Ravelli A. Macrophage activation syndrome. Curr Opin Rheumatol 2002;14:548-52. (Pubitemid 34953793)
2. Sawhney S, Woo P, Murray KJ. Macrophage activation syndrome: a potentially fatal complication of rheumatic disorders. Arch Dis Child 2001;85:421-6. (Pubitemid 33702300)
3. Aeberli D, Oertle S, Mauron H, Reichenbach S, Jordi B, Villiger PM. Inhibition of the TNF-pathway: use of infliximab and etanercept as remission-inducing agents in cases of therapy-resistant chronic inflammatory disorders. Swiss Med Wkly 2002;132:414-22. (Pubitemid 35303463)
4. Makay B, Yilmaz S, Turkyilmaz Z, Unal N, Oren H, Unsal E. Etanercept for therapy-resistant macrophage activation syndrome. Pediatr Blood Cancer 2008;50:419-21.
5. Kelly A, Ramanan AV. Recognition and management of macrophage activation syndrome in juvenile arthritis. Curr Opin Rheumatol 2007;19:477-81. (Pubitemid 47344241)
6. Ravelli A, Magni-Manzoni S, Pistorio A, Besana C, Foti T, Ruperto N, et al. Preliminary diagnostic guidelines for macrophage activation syndrome complicating systemic juvenile idiopathic arthritis. J Pediatr 2005;146:598-604. (Pubitemid 40616243)
7. de Benedetti F, Pignatti P, Massa M, Sartirana P, Ravelli A, Cassani G, et al. Soluble tumour necrosis factor receptor levels reflect coagulation abnormalities in systemic juvenile chronic arthritis. Br J Rheumatol 1997;36:581-8.
8. Shimizu M, Yokoyama T, Yamada K, Kaneda H, Wada H, Wada T, et al. Distinct cytokine profiles of systemic-onset juvenile idiopathic arthritis-associated macrophage activation syndrome with particular emphasis on the role of interleukin-18 in its pathogenesis. Rheumatology (Oxford) 2010. doi:10.1093/rheumatology/keq133.
9. Ozgen B, Karli-Oguz K, Sarikaya B, Tavil B, Gurgey A. Diffusionweighted cranial MR imaging findings in a patient with hemophagocytic syndrome. AJNR Am J Neuroradiol 2006;27:1312-14. (Pubitemid 44897648)
10. Haddad E, Sulis ML, Jabado N, Blanche S, Fischer A, Tardieu M. Frequency and severity of central nervous system lesions in hemophagocytic lymphohistiocytosis. Blood 1997;89:794-800. (Pubitemid 27121272)